A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia

American Journal of Hematology

Volumn 87, Issue 6, 2012, Pages 628-631

  D'Arena, Giovanni ^a   D'Auria, Fiorella ^a   Simeon, Vittorio ^a   Laurenti, Luca ^b   Deaglio, Silvia ^c   Mansueto, Giovanna ^a   Del Principe, Maria Ilaria ^d   Statuto, Teodora ^a   Pietrantuono, Giuseppe ^a   Guariglia, Roberto ^a   Innocenti, Idanna ^b   Martorelli, Maria Carmen ^a   Villani, Oreste ^a   De Feo, Vincenzo ^e   Del Poeta, Giovanni ^d   Musto, Pellegrino ^a  

^a REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; IMMUNOGLOBULIN HEAVY CHAIN;

ADULT; AGED; B LYMPHOCYTE; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CYTOGENETICS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC RISK; HIGH RISK PATIENT; HUMAN; LETTER; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; THROMBOCYTE COUNT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS; WATCHFUL WAITING;

EID: 84861348588     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23170     Document Type: Letter

References (21)

1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
2. Shanafelt TD. Predicting clinical outcome in CLL: How and why. Hematology Am Soc Hematol Educ Program 2009: 421-429.
3. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
4. Binet JL, Leporier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: Prognostic significance. Cancer 1977; 40: 855-864.
5. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on chronic lymphocytic leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
6. Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med 2011; 365: 2497-2506.
7. Sakaguchi S. Regulatory T cells: History and perspective. Methods Mol Biol 2011; 707: 3-17.
8. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006; 108: 804-811.
9. Giannopoulos K, Schmitt M, Kowal M, et al. Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 2008; 20: 677-682.
10. Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4+CD25hiFoxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 788-801.
11. D'Arena G, Laurenti L, Minervini MM, et al. Regulatory T-cell number is increased in chronic lymphocytic leukemia and correlates with progressive disease. Leuk Res 2011; 35: 363-368.
12. Ziegler SF. FOXP3: Of mice and men. Annu Rev Immunol 2006; 24: 209-226.
13. Liu W, Putnam AL, Xu-Yu Z, Szot GL, et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ Treg cells. J Exp Med 2006; 203: 1710-1711.
14. Seddiki N, Santner-Nanan B, Martinson J, et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-1700.
15. Weiss L, Melchardt T, Egle A, et al. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. Cancer 2011; 117: 2163-2169.
16. Hamblin AD, Hamblin TJ. The immunodeficiency of chronic lymphocytic leukemia. Br Med Bull 2008; 87: 49-52.
17. Christopoulos P, Pfeifer D, Bartholomé K, et al. Definition and characterization of the systemic T-cell dysregulation in untreated indolent B-cell lymphoma and very early CLL. Blood 2011; 117: 3836-3846.
18. Jak M, Mous R, Remmerswaal EBM, et al. Enhanced formation and survival of CD4+CD25+CD25hiFoxP3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma 2009; 50: 788-801.
19. D'Arena G, Rossi G, Minervini MM, et al. Circulating regulatory T cells in "clinical" monoclonal B-cell lymphocytosis. Int J Immunopathol Pharmacol 2011; 24: 915-923.
20. D'Arena G, Deaglio S, Laurenti L, et al. Targeting regulatory T cells for anticancer therapy. Mini Rev Med Chem 2011; 11: 480-485.
21. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA. CD4+CD25 high regulatory cells in human peripheral blood. J Immunol 2001; 167: 124-153.